Since GLP-1 receptor agonists showed no significant effect on diabetic retinopathy risk, policies should focus on broader diabetes management strategies that strengthen prevention, early detection, and integrated care for diabetic complications. This evidence concerns the gene GLP1R and diabetes mellitus.